Market openADR

Adagene/$ADAG

14:30

22:10

05:45

13:25

21:00

1D1W1MYTD1Y5YMAX

About Adagene

Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.

Ticker

$ADAG

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Suzhou, China

Employees

174

Website

www.adagene.com

Adagene Metrics

BasicAdvanced

$80M

-

-$0.72

0.65 -

Price and volume

Market cap

$80M

Beta

0.65

52-week high

$4.38

52-week low

$1.74

Average daily volume

69K

Financial strength

Current ratio

2.5

Quick ratio

2.422

Long term debt to equity

8.26

Total debt to equity

36.74

Interest coverage (TTM)

-38.43%

Management effectiveness

Return on assets (TTM)

-19.59%

Return on equity (TTM)

-45.70%

Valuation

Price to revenue (TTM)

97.166

Price to book

1.41

Price to tangible book (TTM)

1.41

Price to free cash flow (TTM)

-2.784

Growth

Revenue change (TTM)

-96.40%

Earnings per share change (TTM)

-15.23%

3-year revenue growth (CAGR)

-22.47%

3-year earnings per share growth (CAGR)

-33.86%

What the Analysts think about Adagene

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Adagene stock.

Adagene Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Adagene Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Adagene News

AllArticlesVideos

Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

GlobeNewsWire·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ADAG

$

Capital at risk

Market openADR

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Adagene stock?

Adagene (ADAG) has a market cap of $80M as of January 15, 2025.

What is the P/E ratio for Adagene stock?

The price to earnings (P/E) ratio for Adagene (ADAG) stock is 0 as of January 15, 2025.

Does Adagene stock pay dividends?

No, Adagene (ADAG) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Adagene dividend payment date?

Adagene (ADAG) stock does not pay dividends to its shareholders.

What is the beta indicator for Adagene?

Adagene (ADAG) has a beta rating of 0.65. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.